Novo Nordisk's Sell-Off Has Gone Too Far

• click to rate

  Posted by Two Blokes Jul 6 - Filed in Stock - 5 views
  
  Novo Nordisk's recent sell-off is overdone; current fears around pricing and CagriSema are temporary, creating a compelling buying opportunity. The company's fundamentals remain strong, with robust sales growth in Ozempic and Wegovy, and a promising pipeline including oral semaglutide and CagriSema. Regulatory and commercial initiatives should drive patients back to branded GLP-1s, supporting a rebound in sales and earnings through 2025-2026.